259 related articles for article (PubMed ID: 25591066)
1. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer.
Njar VC; Brodie AM
J Med Chem; 2015 Mar; 58(5):2077-87. PubMed ID: 25591066
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.
Vasaitis T; Belosay A; Schayowitz A; Khandelwal A; Chopra P; Gediya LK; Guo Z; Fang HB; Njar VC; Brodie AM
Mol Cancer Ther; 2008 Aug; 7(8):2348-57. PubMed ID: 18723482
[TBL] [Abstract][Full Text] [Related]
3. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
4. Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.
Purushottamachar P; Godbole AM; Gediya LK; Martin MS; Vasaitis TS; Kwegyir-Afful AK; Ramalingam S; Ates-Alagoz Z; Njar VC
J Med Chem; 2013 Jun; 56(12):4880-98. PubMed ID: 23713567
[TBL] [Abstract][Full Text] [Related]
5. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.
Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA
Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590
[TBL] [Abstract][Full Text] [Related]
6. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
Gianti E; Zauhar RJ
J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
[TBL] [Abstract][Full Text] [Related]
7. Steroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities.
Alyamani M; Li Z; Berk M; Li J; Tang J; Upadhyay S; Auchus RJ; Sharifi N
Cell Chem Biol; 2017 Jul; 24(7):825-832.e6. PubMed ID: 28648378
[TBL] [Abstract][Full Text] [Related]
8. [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].
Neuzillet Y; Flamand V; Lebdai S; Villers A; Lebret T
Prog Urol; 2013 Oct; 23 Suppl 1():S34-43. PubMed ID: 24314737
[TBL] [Abstract][Full Text] [Related]
9. CYP17 inhibitors for prostate cancer therapy.
Vasaitis TS; Bruno RD; Njar VC
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):23-31. PubMed ID: 21092758
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.
Bedoya DJ; Mitsiades N
Expert Rev Anticancer Ther; 2012 Jan; 12(1):1-3. PubMed ID: 22149426
[No Abstract] [Full Text] [Related]
11. Targeting CYP17: established and novel approaches in prostate cancer.
Yap TA; Carden CP; Attard G; de Bono JS
Curr Opin Pharmacol; 2008 Aug; 8(4):449-57. PubMed ID: 18619560
[TBL] [Abstract][Full Text] [Related]
12. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Bird IM; Abbott DH
J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.
Bruno RD; Vasaitis TS; Gediya LK; Purushottamachar P; Godbole AM; Ates-Alagoz Z; Brodie AM; Njar VC
Steroids; 2011 Nov; 76(12):1268-79. PubMed ID: 21729712
[TBL] [Abstract][Full Text] [Related]
14. Galeterone for the treatment of advanced prostate cancer: the evidence to date.
Bastos DA; Antonarakis ES
Drug Des Devel Ther; 2016; 10():2289-97. PubMed ID: 27486306
[TBL] [Abstract][Full Text] [Related]
15. Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer.
Montgomery B; Eisenberger MA; Rettig MB; Chu F; Pili R; Stephenson JJ; Vogelzang NJ; Koletsky AJ; Nordquist LT; Edenfield WJ; Mamlouk K; Ferrante KJ; Taplin ME
Clin Cancer Res; 2016 Mar; 22(6):1356-63. PubMed ID: 26527750
[TBL] [Abstract][Full Text] [Related]
16. Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases.
Salvador JA; Pinto RM; Silvestre SM
J Steroid Biochem Mol Biol; 2013 Sep; 137():199-222. PubMed ID: 23688836
[TBL] [Abstract][Full Text] [Related]
17. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.
Soifer HS; Souleimanian N; Wu S; Voskresenskiy AM; Collak FK; Cinar B; Stein CA
J Biol Chem; 2012 Feb; 287(6):3777-87. PubMed ID: 22174412
[TBL] [Abstract][Full Text] [Related]
18. Salinization Dramatically Enhance the Anti-Prostate Cancer Efficacies of AR/AR-V7 and Mnk1/2 Molecular Glue Degraders, Galeterone and VNPP433-3β Which Outperform Docetaxel and Enzalutamide in CRPC CWR22Rv1 Xenograft Mouse Model.
Thankan RS; Thomas E; Purushottamachar P; Weber DJ; Njar VCO
Bioorg Chem; 2023 Oct; 139():106700. PubMed ID: 37392559
[TBL] [Abstract][Full Text] [Related]
19. Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model.
Handratta VD; Jelovac D; Long BJ; Kataria R; Nnane IP; Njar VC; Brodie AM
J Steroid Biochem Mol Biol; 2004 Oct; 92(3):155-65. PubMed ID: 15555909
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumour effects and pharmacokinetic profile of 17-(5'-isoxazolyl)androsta-4,16-dien-3-one (L-39) in mice: an inhibitor of androgen synthesis.
Nnane IP; Long BJ; Ling YZ; Grigoryev DN; Brodie AM
Br J Cancer; 2000 Jul; 83(1):74-82. PubMed ID: 10883671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
